4 results

  • ferring pharmaceuticals inc.

    (progesterone)
    Ferring Pharmaceuticals Inc.
    MILPROSA™ is indicated for supporting embryo implantation and early pregnancy (up to 10 weeks post-embryo transfer) by supplementing corpus luteal function in assisted reproductive technology (ART) for infertile women aged 34 and younger. Its efficacy is not established for women 35 and older.

  • firmagon

    (Degarelix)
    Ferring Pharmaceuticals Inc.
    FIRMAGON® is indicated for the treatment of patients with advanced prostate cancer.

  • rebyota

    (Donor Human Stool)
    Ferring Pharmaceuticals Inc.
    REBYOTA is indicated for preventing the recurrence of Clostridioides difficile infection (CDI) in adults aged 18 and older after antibiotic treatment for recurrent CDI. It is not intended for the treatment of CDI.

  • zomacton

    (somatropin)
    Ferring Pharmaceuticals Inc.
    ZOMACTON is indicated for pediatric patients with growth failure due to insufficient growth hormone secretion, Turner syndrome, idiopathic short stature, SHOX deficiency, and short stature from being born small for gestational age. In adults, it is used for GH replacement therapy in those with GH deficiency.